ERBB2 and breast cancer: Several groups have now presented evidence that HER2-positive CTCs can be detected in patients with HER2-negative primary breast cancer during follow-up (Braun et al, 2001; Zidan et al, 2005; Wulfing et al, 2006; Fehm et al, 2010).